Chemical Compound
GSK J1; GSK J1; GSK-J1; ss-Alanine, N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-; N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-ss-alanine; 3-[[2-(2-Pyridyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)p
CAS Registry Number
1373422-53-7
Primary record
GSK J1; GSK J1; GSK-J1; ss-Alanine, N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-; N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-ss-alanine; 3-[[2-(2-Pyridyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)p
- 库存
- 6,672 克
- 纯度
- 99.2 %
- CAS
- 1373422-53-7
化合物标识与属性
- CAS
- 1373422-53-7
- PubChem CID
- 56963315
- SMILES
- C1CN(CCC2=CC=CC=C21)C3=NC(=NC(=C3)NCCC(=O)O)C4=CC=CC=N4
- Canonical SMILES
- O=C(O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1
名称与同义词
- GSK-J1
- GSK J1
- 1373422-53-7
- GSKJ1
- RefChem:1086195
- D0S3DD
- GSKJ1; GSK-J1
- GSK-J1?
- MLS006010249
- MFCD22683851
- C22H23N5O2
- GTPL7027
- orb1300411
- CHEMBL3188597
- Histone demethylase inhibitor J1
- SCHEMBL10157115
- SCHEMBL29353127
- SCHEMBL29371558
- BDBM60875
- AOB3940
- EX-A571
- CHEBI:131152
- DTXSID101025614
- BCP08262
- EX-A1744
- 2442AH
- EBC-14080
- HB1405
- s7581
- ZINC95616592
- AKOS024458240
- CCG-268518
- CS-3322
- GSK-J1, >=98% (HPLC)
- SB19353
- 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid
- NCGC00347943-01
- NCGC00347943-09
- AC-36042
- AK316493
- AS-16773
- DA-53766
- HY-15648
- SMR004701325
- N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-beta-alanine
- 3-((2-(Pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)pyrimidin-4-yl)amino)propanoic acid
- FT-0700180
- 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid
- J3.207.499E
- A12918
- EN300-126471
- A900433
- A920905
- BRD-K32847255-001-01-1
- Q27077924
- n-[2-(2-methyl-1h-indol-3-yl)ethyl]-4-pyridinecarboxamide
- 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid
- N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-?-alanine
- 3-((2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl)amino)propanoic acid
- 3-(6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-ylamino)propanoic acid
- 3-[[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzoazepine-3-yl)pyrimidine-4-yl]amino]propanoic acid
- 3-[[2-(2-pyridyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoic acid
- 3-[2-(2-Pyridyl)-6-(2,3,4,5-tetrahydro-1H-3-benzoazepine-3-yl)pyrimidine-4-ylamino]propionic acid
- GSK J1; GSK J1; GSK-J1; ss-Alanine, N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-; N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-ss-alanine; 3-[[2-(2-Pyridyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)p
- K0I
- N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4- pyrimidinyl]-EC-alanine
- N-[2-(2-Pyridinyl)-6-(1,2,4,5-Tetrahydro-3H-3-Benzazepin-3-Yl)-4-Pyrimidinyl]-| cent-Alanine
- N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-|A-alanine
- N-[2-(pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)pyrimidin-4-yl]-beta-alanine